{"id":3548,"date":"2021-03-05T14:52:56","date_gmt":"2021-03-05T12:52:56","guid":{"rendered":"https:\/\/info.e-med.co.il\/remsima\/?p=3548"},"modified":"2023-10-25T14:53:30","modified_gmt":"2023-10-25T11:53:30","slug":"randomized-controlled-trial-subcutaneous-vs-intravenous-infliximab-ct-p13-maintenance-in-inflammatory-bowel-disease","status":"publish","type":"post","link":"https:\/\/info.e-med.co.il\/remsima\/randomized-controlled-trial-subcutaneous-vs-intravenous-infliximab-ct-p13-maintenance-in-inflammatory-bowel-disease\/","title":{"rendered":"Randomized Controlled Trial: Subcutaneous vs Intravenous Infliximab CT-P13 Maintenance in Inflammatory Bowel Disease"},"content":{"rendered":"<h3 class=\"title\" dir=\"ltr\" style=\"text-align: left;\">Abstract<\/h3>\n<div id=\"eng-abstract\" class=\"abstract-content selected\">\n<p dir=\"ltr\" style=\"text-align: left;\"><strong class=\"sub-title\">Background &amp; aims:\u00a0<\/strong>This study compared pharmacokinetics, symptomatic and endoscopic efficacy, safety, and immunogenicity of a subcutaneous formulation of the infliximab biosimilar CT-P13 (CT-P13 SC) vs intravenous CT-P13 (CT-P13 IV) in patients with inflammatory bowel disease (IBD).<\/p>\n<p style=\"text-align: right;\"><strong><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/33676969\/\" target=\"_blank\" rel=\"noopener\">\u05dc\u05d4\u05de\u05e9\u05da \u05e7\u05e8\u05d9\u05d0\u05d4<\/a><\/strong><\/p>\n<\/div>\n<p dir=\"ltr\">Schreiber S, Ben-Horin S, Leszczyszyn J, Dudkowiak R, Lahat A, Gawdis-Wojnarska B, Pukitis A, Horynski M, Farkas K, Kierkus J, Kowalski M, Lee SJ, Kim SH, Suh JH, Kim MR, Lee SG, Ye BD, Reinisch W. Randomized Controlled Trial: Subcutaneous vs Intravenous Infliximab CT-P13 Maintenance in Inflammatory Bowel Disease. Gastroenterology. 2021 Jun;160(7):2340-2353. doi: 10.1053\/j.gastro.2021.02.068. Epub 2021 Mar 5. PMID: 33676969.<\/p>\n","protected":false},"excerpt":{"rendered":"<p dir=\"ltr\"><strong>Schreiber et.al.; Gastroenterology 2021;160:2340\u20132353 \u00a0<\/strong><\/p>\n","protected":false},"author":2,"featured_media":3549,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"om_disable_all_campaigns":false,"footnotes":""},"categories":[28,26,24],"tags":[],"class_list":["post-3548","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-article-en","category-research","category-updates-news"],"aioseo_notices":[],"aioseo_head":"\n\t\t<!-- All in One SEO 4.9.9 - aioseo.com -->\n\t<meta name=\"description\" content=\"Schreiber et.al.; Gastroenterology 2021;160:2340\u20132353\" \/>\n\t<meta name=\"robots\" content=\"max-image-preview:large\" \/>\n\t<meta name=\"author\" content=\"&#039;\u05de\u05e2\u05e8\u05db\u05ea \u05d0\u05d9\u05de\u05d3&#039;\"\/>\n\t<meta name=\"keywords\" content=\"article,\u05de\u05d7\u05e7\u05e8\u05d9\u05dd \u05d5\u05e4\u05e8\u05e1\u05d5\u05de\u05d9\u05dd,\u05e2\u05d3\u05db\u05d5\u05e0\u05d9\u05dd\" \/>\n\t<link rel=\"canonical\" href=\"https:\/\/info.e-med.co.il\/remsima\/randomized-controlled-trial-subcutaneous-vs-intravenous-infliximab-ct-p13-maintenance-in-inflammatory-bowel-disease\/\" \/>\n\t<meta name=\"generator\" content=\"All in One SEO (AIOSEO) 4.9.9\" \/>\n\t\t<meta property=\"og:locale\" content=\"he_IL\" \/>\n\t\t<meta property=\"og:site_name\" content=\"Remsima | \u05e8\u05de\u05e1\u05d9\u05de\u05d4 120 \u05de&quot;\u05d2\/\u05de&quot;\u05dc \u05ea\u05ea -\u05e2\u05d5\u05e8\u05d9 \u05d4\u05d9\u05e0\u05d5 \u05d4\u05d0\u05d9\u05e0\u05e4\u05dc\u05d9\u05e7\u05e1\u05d9\u05de\u05d0\u05d1 \u05d4\u05d9\u05d7\u05d9\u05d3 \u05db\u05d9\u05d5\u05dd \u05d4\u05e0\u05d9\u05ea\u05df \u05d1\u05de\u05ea\u05df \u05ea\u05ea-\u05e2\u05d5\u05e8\u05d9\" \/>\n\t\t<meta property=\"og:type\" content=\"article\" \/>\n\t\t<meta property=\"og:title\" content=\"Randomized Controlled Trial: Subcutaneous vs Intravenous Infliximab CT-P13 Maintenance in Inflammatory Bowel Disease | Remsima\" \/>\n\t\t<meta property=\"og:description\" content=\"Schreiber et.al.; Gastroenterology 2021;160:2340\u20132353\" \/>\n\t\t<meta property=\"og:url\" content=\"https:\/\/info.e-med.co.il\/remsima\/randomized-controlled-trial-subcutaneous-vs-intravenous-infliximab-ct-p13-maintenance-in-inflammatory-bowel-disease\/\" \/>\n\t\t<meta property=\"article:published_time\" content=\"2021-03-05T12:52:56+00:00\" \/>\n\t\t<meta property=\"article:modified_time\" content=\"2023-10-25T11:53:30+00:00\" \/>\n\t\t<meta name=\"twitter:card\" content=\"summary\" \/>\n\t\t<meta name=\"twitter:title\" content=\"Randomized Controlled Trial: Subcutaneous vs Intravenous Infliximab CT-P13 Maintenance in Inflammatory Bowel Disease | Remsima\" \/>\n\t\t<meta name=\"twitter:description\" content=\"Schreiber et.al.; Gastroenterology 2021;160:2340\u20132353\" \/>\n\t\t<script type=\"application\/ld+json\" class=\"aioseo-schema\">\n\t\t\t{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/info.e-med.co.il\\\/remsima\\\/randomized-controlled-trial-subcutaneous-vs-intravenous-infliximab-ct-p13-maintenance-in-inflammatory-bowel-disease\\\/#article\",\"name\":\"Randomized Controlled Trial: Subcutaneous vs Intravenous Infliximab CT-P13 Maintenance in Inflammatory Bowel Disease | Remsima\",\"headline\":\"Randomized Controlled Trial: Subcutaneous vs Intravenous Infliximab CT-P13 Maintenance in Inflammatory Bowel Disease\",\"author\":{\"@id\":\"https:\\\/\\\/info.e-med.co.il\\\/remsima\\\/author\\\/naama2shomroni23\\\/#author\"},\"publisher\":{\"@id\":\"https:\\\/\\\/info.e-med.co.il\\\/remsima\\\/#organization\"},\"image\":{\"@type\":\"ImageObject\",\"url\":\"https:\\\/\\\/info.e-med.co.il\\\/remsima\\\/files\\\/2023\\\/10\\\/99268664-bowel.jpg\",\"width\":477,\"height\":358,\"caption\":\"human colon\"},\"datePublished\":\"2021-03-05T14:52:56+02:00\",\"dateModified\":\"2023-10-25T14:53:30+03:00\",\"inLanguage\":\"he-IL\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/info.e-med.co.il\\\/remsima\\\/randomized-controlled-trial-subcutaneous-vs-intravenous-infliximab-ct-p13-maintenance-in-inflammatory-bowel-disease\\\/#webpage\"},\"isPartOf\":{\"@id\":\"https:\\\/\\\/info.e-med.co.il\\\/remsima\\\/randomized-controlled-trial-subcutaneous-vs-intravenous-infliximab-ct-p13-maintenance-in-inflammatory-bowel-disease\\\/#webpage\"},\"articleSection\":\"Article, \\u05de\\u05d7\\u05e7\\u05e8\\u05d9\\u05dd \\u05d5\\u05e4\\u05e8\\u05e1\\u05d5\\u05de\\u05d9\\u05dd, \\u05e2\\u05d3\\u05db\\u05d5\\u05e0\\u05d9\\u05dd\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/info.e-med.co.il\\\/remsima\\\/randomized-controlled-trial-subcutaneous-vs-intravenous-infliximab-ct-p13-maintenance-in-inflammatory-bowel-disease\\\/#breadcrumblist\",\"itemListElement\":[{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/info.e-med.co.il\\\/remsima#listItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/info.e-med.co.il\\\/remsima\",\"nextItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/info.e-med.co.il\\\/remsima\\\/updates-news\\\/#listItem\",\"name\":\"\\u05e2\\u05d3\\u05db\\u05d5\\u05e0\\u05d9\\u05dd\"}},{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/info.e-med.co.il\\\/remsima\\\/updates-news\\\/#listItem\",\"position\":2,\"name\":\"\\u05e2\\u05d3\\u05db\\u05d5\\u05e0\\u05d9\\u05dd\",\"item\":\"https:\\\/\\\/info.e-med.co.il\\\/remsima\\\/updates-news\\\/\",\"nextItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/info.e-med.co.il\\\/remsima\\\/research\\\/#listItem\",\"name\":\"\\u05de\\u05d7\\u05e7\\u05e8\\u05d9\\u05dd \\u05d5\\u05e4\\u05e8\\u05e1\\u05d5\\u05de\\u05d9\\u05dd\"},\"previousItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/info.e-med.co.il\\\/remsima#listItem\",\"name\":\"Home\"}},{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/info.e-med.co.il\\\/remsima\\\/research\\\/#listItem\",\"position\":3,\"name\":\"\\u05de\\u05d7\\u05e7\\u05e8\\u05d9\\u05dd \\u05d5\\u05e4\\u05e8\\u05e1\\u05d5\\u05de\\u05d9\\u05dd\",\"item\":\"https:\\\/\\\/info.e-med.co.il\\\/remsima\\\/research\\\/\",\"nextItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/info.e-med.co.il\\\/remsima\\\/randomized-controlled-trial-subcutaneous-vs-intravenous-infliximab-ct-p13-maintenance-in-inflammatory-bowel-disease\\\/#listItem\",\"name\":\"Randomized Controlled Trial: Subcutaneous vs Intravenous Infliximab CT-P13 Maintenance in Inflammatory Bowel Disease\"},\"previousItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/info.e-med.co.il\\\/remsima\\\/updates-news\\\/#listItem\",\"name\":\"\\u05e2\\u05d3\\u05db\\u05d5\\u05e0\\u05d9\\u05dd\"}},{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/info.e-med.co.il\\\/remsima\\\/randomized-controlled-trial-subcutaneous-vs-intravenous-infliximab-ct-p13-maintenance-in-inflammatory-bowel-disease\\\/#listItem\",\"position\":4,\"name\":\"Randomized Controlled Trial: Subcutaneous vs Intravenous Infliximab CT-P13 Maintenance in Inflammatory Bowel Disease\",\"previousItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/info.e-med.co.il\\\/remsima\\\/research\\\/#listItem\",\"name\":\"\\u05de\\u05d7\\u05e7\\u05e8\\u05d9\\u05dd \\u05d5\\u05e4\\u05e8\\u05e1\\u05d5\\u05de\\u05d9\\u05dd\"}}]},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/info.e-med.co.il\\\/remsima\\\/#organization\",\"name\":\"\\u05e4\\u05d0\\u05d3\\u05d0\\u05d2\\u05d9\\u05e1 \\u05d9\\u05e9\\u05e8\\u05d0\\u05dc \\u05e1\\u05d5\\u05db\\u05e0\\u05d5\\u05d9\\u05d5\\u05ea \\u05d1\\u05e2\\\"\\u05de\",\"description\":\"\\u05e8\\u05de\\u05e1\\u05d9\\u05de\\u05d4 120 \\u05de\\\"\\u05d2\\\/\\u05de\\\"\\u05dc \\u05ea\\u05ea -\\u05e2\\u05d5\\u05e8\\u05d9 \\u05d4\\u05d9\\u05e0\\u05d5 \\u05d4\\u05d0\\u05d9\\u05e0\\u05e4\\u05dc\\u05d9\\u05e7\\u05e1\\u05d9\\u05de\\u05d0\\u05d1 \\u05d4\\u05d9\\u05d7\\u05d9\\u05d3 \\u05db\\u05d9\\u05d5\\u05dd \\u05d4\\u05e0\\u05d9\\u05ea\\u05df \\u05d1\\u05de\\u05ea\\u05df \\u05ea\\u05ea-\\u05e2\\u05d5\\u05e8\\u05d9\",\"url\":\"https:\\\/\\\/info.e-med.co.il\\\/remsima\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"url\":\"https:\\\/\\\/info.e-med.co.il\\\/remsima\\\/files\\\/2023\\\/11\\\/remsima_150.jpg\",\"@id\":\"https:\\\/\\\/info.e-med.co.il\\\/remsima\\\/randomized-controlled-trial-subcutaneous-vs-intravenous-infliximab-ct-p13-maintenance-in-inflammatory-bowel-disease\\\/#organizationLogo\",\"width\":150,\"height\":150},\"image\":{\"@id\":\"https:\\\/\\\/info.e-med.co.il\\\/remsima\\\/randomized-controlled-trial-subcutaneous-vs-intravenous-infliximab-ct-p13-maintenance-in-inflammatory-bowel-disease\\\/#organizationLogo\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/info.e-med.co.il\\\/remsima\\\/author\\\/naama2shomroni23\\\/#author\",\"url\":\"https:\\\/\\\/info.e-med.co.il\\\/remsima\\\/author\\\/naama2shomroni23\\\/\",\"name\":\"'\\u05de\\u05e2\\u05e8\\u05db\\u05ea \\u05d0\\u05d9\\u05de\\u05d3'\",\"image\":{\"@type\":\"ImageObject\",\"@id\":\"https:\\\/\\\/info.e-med.co.il\\\/remsima\\\/randomized-controlled-trial-subcutaneous-vs-intravenous-infliximab-ct-p13-maintenance-in-inflammatory-bowel-disease\\\/#authorImage\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/4a33eb712ef50ecea3e80558c3ebca581471b3c91aeab90167c90d04c73f5e3b?s=96&d=mm&r=g\",\"width\":96,\"height\":96,\"caption\":\"'\\u05de\\u05e2\\u05e8\\u05db\\u05ea \\u05d0\\u05d9\\u05de\\u05d3'\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/info.e-med.co.il\\\/remsima\\\/randomized-controlled-trial-subcutaneous-vs-intravenous-infliximab-ct-p13-maintenance-in-inflammatory-bowel-disease\\\/#webpage\",\"url\":\"https:\\\/\\\/info.e-med.co.il\\\/remsima\\\/randomized-controlled-trial-subcutaneous-vs-intravenous-infliximab-ct-p13-maintenance-in-inflammatory-bowel-disease\\\/\",\"name\":\"Randomized Controlled Trial: Subcutaneous vs Intravenous Infliximab CT-P13 Maintenance in Inflammatory Bowel Disease | Remsima\",\"description\":\"Schreiber et.al.; Gastroenterology 2021;160:2340\\u20132353\",\"inLanguage\":\"he-IL\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/info.e-med.co.il\\\/remsima\\\/#website\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/info.e-med.co.il\\\/remsima\\\/randomized-controlled-trial-subcutaneous-vs-intravenous-infliximab-ct-p13-maintenance-in-inflammatory-bowel-disease\\\/#breadcrumblist\"},\"author\":{\"@id\":\"https:\\\/\\\/info.e-med.co.il\\\/remsima\\\/author\\\/naama2shomroni23\\\/#author\"},\"creator\":{\"@id\":\"https:\\\/\\\/info.e-med.co.il\\\/remsima\\\/author\\\/naama2shomroni23\\\/#author\"},\"image\":{\"@type\":\"ImageObject\",\"url\":\"https:\\\/\\\/info.e-med.co.il\\\/remsima\\\/files\\\/2023\\\/10\\\/99268664-bowel.jpg\",\"@id\":\"https:\\\/\\\/info.e-med.co.il\\\/remsima\\\/randomized-controlled-trial-subcutaneous-vs-intravenous-infliximab-ct-p13-maintenance-in-inflammatory-bowel-disease\\\/#mainImage\",\"width\":477,\"height\":358,\"caption\":\"human colon\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/info.e-med.co.il\\\/remsima\\\/randomized-controlled-trial-subcutaneous-vs-intravenous-infliximab-ct-p13-maintenance-in-inflammatory-bowel-disease\\\/#mainImage\"},\"datePublished\":\"2021-03-05T14:52:56+02:00\",\"dateModified\":\"2023-10-25T14:53:30+03:00\"},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/info.e-med.co.il\\\/remsima\\\/#website\",\"url\":\"https:\\\/\\\/info.e-med.co.il\\\/remsima\\\/\",\"name\":\"Remsima\",\"description\":\"\\u05e8\\u05de\\u05e1\\u05d9\\u05de\\u05d4 120 \\u05de\\\"\\u05d2\\\/\\u05de\\\"\\u05dc \\u05ea\\u05ea -\\u05e2\\u05d5\\u05e8\\u05d9 \\u05d4\\u05d9\\u05e0\\u05d5 \\u05d4\\u05d0\\u05d9\\u05e0\\u05e4\\u05dc\\u05d9\\u05e7\\u05e1\\u05d9\\u05de\\u05d0\\u05d1 \\u05d4\\u05d9\\u05d7\\u05d9\\u05d3 \\u05db\\u05d9\\u05d5\\u05dd \\u05d4\\u05e0\\u05d9\\u05ea\\u05df \\u05d1\\u05de\\u05ea\\u05df \\u05ea\\u05ea-\\u05e2\\u05d5\\u05e8\\u05d9\",\"inLanguage\":\"he-IL\",\"publisher\":{\"@id\":\"https:\\\/\\\/info.e-med.co.il\\\/remsima\\\/#organization\"}}]}\n\t\t<\/script>\n\t\t<!-- All in One SEO -->\n\n","aioseo_head_json":{"title":"Randomized Controlled Trial: Subcutaneous vs Intravenous Infliximab CT-P13 Maintenance in Inflammatory Bowel Disease | Remsima","description":"Schreiber et.al.; Gastroenterology 2021;160:2340\u20132353","canonical_url":"https:\/\/info.e-med.co.il\/remsima\/randomized-controlled-trial-subcutaneous-vs-intravenous-infliximab-ct-p13-maintenance-in-inflammatory-bowel-disease\/","robots":"max-image-preview:large","keywords":"article,\u05de\u05d7\u05e7\u05e8\u05d9\u05dd \u05d5\u05e4\u05e8\u05e1\u05d5\u05de\u05d9\u05dd,\u05e2\u05d3\u05db\u05d5\u05e0\u05d9\u05dd","webmasterTools":{"miscellaneous":""},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/info.e-med.co.il\/remsima\/randomized-controlled-trial-subcutaneous-vs-intravenous-infliximab-ct-p13-maintenance-in-inflammatory-bowel-disease\/#article","name":"Randomized Controlled Trial: Subcutaneous vs Intravenous Infliximab CT-P13 Maintenance in Inflammatory Bowel Disease | Remsima","headline":"Randomized Controlled Trial: Subcutaneous vs Intravenous Infliximab CT-P13 Maintenance in Inflammatory Bowel Disease","author":{"@id":"https:\/\/info.e-med.co.il\/remsima\/author\/naama2shomroni23\/#author"},"publisher":{"@id":"https:\/\/info.e-med.co.il\/remsima\/#organization"},"image":{"@type":"ImageObject","url":"https:\/\/info.e-med.co.il\/remsima\/files\/2023\/10\/99268664-bowel.jpg","width":477,"height":358,"caption":"human colon"},"datePublished":"2021-03-05T14:52:56+02:00","dateModified":"2023-10-25T14:53:30+03:00","inLanguage":"he-IL","mainEntityOfPage":{"@id":"https:\/\/info.e-med.co.il\/remsima\/randomized-controlled-trial-subcutaneous-vs-intravenous-infliximab-ct-p13-maintenance-in-inflammatory-bowel-disease\/#webpage"},"isPartOf":{"@id":"https:\/\/info.e-med.co.il\/remsima\/randomized-controlled-trial-subcutaneous-vs-intravenous-infliximab-ct-p13-maintenance-in-inflammatory-bowel-disease\/#webpage"},"articleSection":"Article, \u05de\u05d7\u05e7\u05e8\u05d9\u05dd \u05d5\u05e4\u05e8\u05e1\u05d5\u05de\u05d9\u05dd, \u05e2\u05d3\u05db\u05d5\u05e0\u05d9\u05dd"},{"@type":"BreadcrumbList","@id":"https:\/\/info.e-med.co.il\/remsima\/randomized-controlled-trial-subcutaneous-vs-intravenous-infliximab-ct-p13-maintenance-in-inflammatory-bowel-disease\/#breadcrumblist","itemListElement":[{"@type":"ListItem","@id":"https:\/\/info.e-med.co.il\/remsima#listItem","position":1,"name":"Home","item":"https:\/\/info.e-med.co.il\/remsima","nextItem":{"@type":"ListItem","@id":"https:\/\/info.e-med.co.il\/remsima\/updates-news\/#listItem","name":"\u05e2\u05d3\u05db\u05d5\u05e0\u05d9\u05dd"}},{"@type":"ListItem","@id":"https:\/\/info.e-med.co.il\/remsima\/updates-news\/#listItem","position":2,"name":"\u05e2\u05d3\u05db\u05d5\u05e0\u05d9\u05dd","item":"https:\/\/info.e-med.co.il\/remsima\/updates-news\/","nextItem":{"@type":"ListItem","@id":"https:\/\/info.e-med.co.il\/remsima\/research\/#listItem","name":"\u05de\u05d7\u05e7\u05e8\u05d9\u05dd \u05d5\u05e4\u05e8\u05e1\u05d5\u05de\u05d9\u05dd"},"previousItem":{"@type":"ListItem","@id":"https:\/\/info.e-med.co.il\/remsima#listItem","name":"Home"}},{"@type":"ListItem","@id":"https:\/\/info.e-med.co.il\/remsima\/research\/#listItem","position":3,"name":"\u05de\u05d7\u05e7\u05e8\u05d9\u05dd \u05d5\u05e4\u05e8\u05e1\u05d5\u05de\u05d9\u05dd","item":"https:\/\/info.e-med.co.il\/remsima\/research\/","nextItem":{"@type":"ListItem","@id":"https:\/\/info.e-med.co.il\/remsima\/randomized-controlled-trial-subcutaneous-vs-intravenous-infliximab-ct-p13-maintenance-in-inflammatory-bowel-disease\/#listItem","name":"Randomized Controlled Trial: Subcutaneous vs Intravenous Infliximab CT-P13 Maintenance in Inflammatory Bowel Disease"},"previousItem":{"@type":"ListItem","@id":"https:\/\/info.e-med.co.il\/remsima\/updates-news\/#listItem","name":"\u05e2\u05d3\u05db\u05d5\u05e0\u05d9\u05dd"}},{"@type":"ListItem","@id":"https:\/\/info.e-med.co.il\/remsima\/randomized-controlled-trial-subcutaneous-vs-intravenous-infliximab-ct-p13-maintenance-in-inflammatory-bowel-disease\/#listItem","position":4,"name":"Randomized Controlled Trial: Subcutaneous vs Intravenous Infliximab CT-P13 Maintenance in Inflammatory Bowel Disease","previousItem":{"@type":"ListItem","@id":"https:\/\/info.e-med.co.il\/remsima\/research\/#listItem","name":"\u05de\u05d7\u05e7\u05e8\u05d9\u05dd \u05d5\u05e4\u05e8\u05e1\u05d5\u05de\u05d9\u05dd"}}]},{"@type":"Organization","@id":"https:\/\/info.e-med.co.il\/remsima\/#organization","name":"\u05e4\u05d0\u05d3\u05d0\u05d2\u05d9\u05e1 \u05d9\u05e9\u05e8\u05d0\u05dc \u05e1\u05d5\u05db\u05e0\u05d5\u05d9\u05d5\u05ea \u05d1\u05e2\"\u05de","description":"\u05e8\u05de\u05e1\u05d9\u05de\u05d4 120 \u05de\"\u05d2\/\u05de\"\u05dc \u05ea\u05ea -\u05e2\u05d5\u05e8\u05d9 \u05d4\u05d9\u05e0\u05d5 \u05d4\u05d0\u05d9\u05e0\u05e4\u05dc\u05d9\u05e7\u05e1\u05d9\u05de\u05d0\u05d1 \u05d4\u05d9\u05d7\u05d9\u05d3 \u05db\u05d9\u05d5\u05dd \u05d4\u05e0\u05d9\u05ea\u05df \u05d1\u05de\u05ea\u05df \u05ea\u05ea-\u05e2\u05d5\u05e8\u05d9","url":"https:\/\/info.e-med.co.il\/remsima\/","logo":{"@type":"ImageObject","url":"https:\/\/info.e-med.co.il\/remsima\/files\/2023\/11\/remsima_150.jpg","@id":"https:\/\/info.e-med.co.il\/remsima\/randomized-controlled-trial-subcutaneous-vs-intravenous-infliximab-ct-p13-maintenance-in-inflammatory-bowel-disease\/#organizationLogo","width":150,"height":150},"image":{"@id":"https:\/\/info.e-med.co.il\/remsima\/randomized-controlled-trial-subcutaneous-vs-intravenous-infliximab-ct-p13-maintenance-in-inflammatory-bowel-disease\/#organizationLogo"}},{"@type":"Person","@id":"https:\/\/info.e-med.co.il\/remsima\/author\/naama2shomroni23\/#author","url":"https:\/\/info.e-med.co.il\/remsima\/author\/naama2shomroni23\/","name":"'\u05de\u05e2\u05e8\u05db\u05ea \u05d0\u05d9\u05de\u05d3'","image":{"@type":"ImageObject","@id":"https:\/\/info.e-med.co.il\/remsima\/randomized-controlled-trial-subcutaneous-vs-intravenous-infliximab-ct-p13-maintenance-in-inflammatory-bowel-disease\/#authorImage","url":"https:\/\/secure.gravatar.com\/avatar\/4a33eb712ef50ecea3e80558c3ebca581471b3c91aeab90167c90d04c73f5e3b?s=96&d=mm&r=g","width":96,"height":96,"caption":"'\u05de\u05e2\u05e8\u05db\u05ea \u05d0\u05d9\u05de\u05d3'"}},{"@type":"WebPage","@id":"https:\/\/info.e-med.co.il\/remsima\/randomized-controlled-trial-subcutaneous-vs-intravenous-infliximab-ct-p13-maintenance-in-inflammatory-bowel-disease\/#webpage","url":"https:\/\/info.e-med.co.il\/remsima\/randomized-controlled-trial-subcutaneous-vs-intravenous-infliximab-ct-p13-maintenance-in-inflammatory-bowel-disease\/","name":"Randomized Controlled Trial: Subcutaneous vs Intravenous Infliximab CT-P13 Maintenance in Inflammatory Bowel Disease | Remsima","description":"Schreiber et.al.; Gastroenterology 2021;160:2340\u20132353","inLanguage":"he-IL","isPartOf":{"@id":"https:\/\/info.e-med.co.il\/remsima\/#website"},"breadcrumb":{"@id":"https:\/\/info.e-med.co.il\/remsima\/randomized-controlled-trial-subcutaneous-vs-intravenous-infliximab-ct-p13-maintenance-in-inflammatory-bowel-disease\/#breadcrumblist"},"author":{"@id":"https:\/\/info.e-med.co.il\/remsima\/author\/naama2shomroni23\/#author"},"creator":{"@id":"https:\/\/info.e-med.co.il\/remsima\/author\/naama2shomroni23\/#author"},"image":{"@type":"ImageObject","url":"https:\/\/info.e-med.co.il\/remsima\/files\/2023\/10\/99268664-bowel.jpg","@id":"https:\/\/info.e-med.co.il\/remsima\/randomized-controlled-trial-subcutaneous-vs-intravenous-infliximab-ct-p13-maintenance-in-inflammatory-bowel-disease\/#mainImage","width":477,"height":358,"caption":"human colon"},"primaryImageOfPage":{"@id":"https:\/\/info.e-med.co.il\/remsima\/randomized-controlled-trial-subcutaneous-vs-intravenous-infliximab-ct-p13-maintenance-in-inflammatory-bowel-disease\/#mainImage"},"datePublished":"2021-03-05T14:52:56+02:00","dateModified":"2023-10-25T14:53:30+03:00"},{"@type":"WebSite","@id":"https:\/\/info.e-med.co.il\/remsima\/#website","url":"https:\/\/info.e-med.co.il\/remsima\/","name":"Remsima","description":"\u05e8\u05de\u05e1\u05d9\u05de\u05d4 120 \u05de\"\u05d2\/\u05de\"\u05dc \u05ea\u05ea -\u05e2\u05d5\u05e8\u05d9 \u05d4\u05d9\u05e0\u05d5 \u05d4\u05d0\u05d9\u05e0\u05e4\u05dc\u05d9\u05e7\u05e1\u05d9\u05de\u05d0\u05d1 \u05d4\u05d9\u05d7\u05d9\u05d3 \u05db\u05d9\u05d5\u05dd \u05d4\u05e0\u05d9\u05ea\u05df \u05d1\u05de\u05ea\u05df \u05ea\u05ea-\u05e2\u05d5\u05e8\u05d9","inLanguage":"he-IL","publisher":{"@id":"https:\/\/info.e-med.co.il\/remsima\/#organization"}}]},"og:locale":"he_IL","og:site_name":"Remsima | \u05e8\u05de\u05e1\u05d9\u05de\u05d4 120 \u05de&quot;\u05d2\/\u05de&quot;\u05dc \u05ea\u05ea -\u05e2\u05d5\u05e8\u05d9 \u05d4\u05d9\u05e0\u05d5 \u05d4\u05d0\u05d9\u05e0\u05e4\u05dc\u05d9\u05e7\u05e1\u05d9\u05de\u05d0\u05d1 \u05d4\u05d9\u05d7\u05d9\u05d3 \u05db\u05d9\u05d5\u05dd \u05d4\u05e0\u05d9\u05ea\u05df \u05d1\u05de\u05ea\u05df \u05ea\u05ea-\u05e2\u05d5\u05e8\u05d9","og:type":"article","og:title":"Randomized Controlled Trial: Subcutaneous vs Intravenous Infliximab CT-P13 Maintenance in Inflammatory Bowel Disease | Remsima","og:description":"Schreiber et.al.; Gastroenterology 2021;160:2340\u20132353","og:url":"https:\/\/info.e-med.co.il\/remsima\/randomized-controlled-trial-subcutaneous-vs-intravenous-infliximab-ct-p13-maintenance-in-inflammatory-bowel-disease\/","article:published_time":"2021-03-05T12:52:56+00:00","article:modified_time":"2023-10-25T11:53:30+00:00","twitter:card":"summary","twitter:title":"Randomized Controlled Trial: Subcutaneous vs Intravenous Infliximab CT-P13 Maintenance in Inflammatory Bowel Disease | Remsima","twitter:description":"Schreiber et.al.; Gastroenterology 2021;160:2340\u20132353"},"aioseo_meta_data":{"post_id":"3548","title":null,"description":null,"keywords":[],"keyphrases":{"focus":{"keyphrase":"","score":0,"analysis":{"keyphraseInTitle":{"score":0,"maxScore":9,"error":1}}},"additional":[]},"canonical_url":null,"og_title":null,"og_description":null,"og_object_type":"default","og_image_type":"default","og_image_custom_url":null,"og_image_custom_fields":null,"og_custom_image_width":null,"og_custom_image_height":null,"og_video":"","og_custom_url":null,"og_article_section":null,"og_article_tags":[],"twitter_use_og":false,"twitter_card":"default","twitter_image_type":"default","twitter_image_custom_url":null,"twitter_image_custom_fields":null,"twitter_title":null,"twitter_description":null,"schema_type":null,"schema_type_options":null,"pillar_content":false,"robots_default":true,"robots_noindex":false,"robots_noarchive":false,"robots_nosnippet":false,"robots_nofollow":false,"robots_noimageindex":false,"robots_noodp":false,"robots_notranslate":false,"robots_max_snippet":"-1","robots_max_videopreview":"-1","robots_max_imagepreview":"none","tabs":null,"priority":null,"frequency":"default","local_seo":null,"breadcrumb_settings":null,"created":"2023-10-25 11:48:51","updated":"2026-05-15 00:39:37","primary_term":null,"og_image_url":null,"og_image_width":null,"og_image_height":null,"twitter_image_url":null,"schema":{"blockGraphs":[],"customGraphs":[],"default":{"data":{"Article":[],"Course":[],"Dataset":[],"FAQPage":[],"Movie":[],"Person":[],"Product":[],"ProductReview":[],"Car":[],"Recipe":[],"Service":[],"SoftwareApplication":[],"WebPage":[]},"graphName":"Article","isEnabled":true},"graphs":[]},"limit_modified_date":false,"ai":null,"seo_analyzer_scan_date":null},"aioseo_breadcrumb":"<div class=\"aioseo-breadcrumbs\"><span class=\"aioseo-breadcrumb\">\n\t\t\t<a href=\"https:\/\/info.e-med.co.il\/remsima\" title=\"Home\">Home<\/a>\n\t\t<\/span><span class=\"aioseo-breadcrumb-separator\">&raquo;<\/span><span class=\"aioseo-breadcrumb\">\n\t\t\t<a href=\"https:\/\/info.e-med.co.il\/remsima\/updates-news\/\" title=\"\u05e2\u05d3\u05db\u05d5\u05e0\u05d9\u05dd\">\u05e2\u05d3\u05db\u05d5\u05e0\u05d9\u05dd<\/a>\n\t\t<\/span><span class=\"aioseo-breadcrumb-separator\">&raquo;<\/span><span class=\"aioseo-breadcrumb\">\n\t\t\t<a href=\"https:\/\/info.e-med.co.il\/remsima\/research\/\" title=\"\u05de\u05d7\u05e7\u05e8\u05d9\u05dd \u05d5\u05e4\u05e8\u05e1\u05d5\u05de\u05d9\u05dd\">\u05de\u05d7\u05e7\u05e8\u05d9\u05dd \u05d5\u05e4\u05e8\u05e1\u05d5\u05de\u05d9\u05dd<\/a>\n\t\t<\/span><span class=\"aioseo-breadcrumb-separator\">&raquo;<\/span><span class=\"aioseo-breadcrumb\">\n\t\t\tRandomized Controlled Trial: Subcutaneous vs Intravenous Infliximab CT-P13 Maintenance in Inflammatory Bowel Disease\n\t\t<\/span><\/div>","aioseo_breadcrumb_json":[{"label":"Home","link":"https:\/\/info.e-med.co.il\/remsima"},{"label":"\u05e2\u05d3\u05db\u05d5\u05e0\u05d9\u05dd","link":"https:\/\/info.e-med.co.il\/remsima\/updates-news\/"},{"label":"\u05de\u05d7\u05e7\u05e8\u05d9\u05dd \u05d5\u05e4\u05e8\u05e1\u05d5\u05de\u05d9\u05dd","link":"https:\/\/info.e-med.co.il\/remsima\/research\/"},{"label":"Randomized Controlled Trial: Subcutaneous vs Intravenous Infliximab CT-P13 Maintenance in Inflammatory Bowel Disease","link":"https:\/\/info.e-med.co.il\/remsima\/randomized-controlled-trial-subcutaneous-vs-intravenous-infliximab-ct-p13-maintenance-in-inflammatory-bowel-disease\/"}],"_links":{"self":[{"href":"https:\/\/info.e-med.co.il\/remsima\/wp-json\/wp\/v2\/posts\/3548","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/info.e-med.co.il\/remsima\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/info.e-med.co.il\/remsima\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/info.e-med.co.il\/remsima\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/info.e-med.co.il\/remsima\/wp-json\/wp\/v2\/comments?post=3548"}],"version-history":[{"count":1,"href":"https:\/\/info.e-med.co.il\/remsima\/wp-json\/wp\/v2\/posts\/3548\/revisions"}],"predecessor-version":[{"id":3550,"href":"https:\/\/info.e-med.co.il\/remsima\/wp-json\/wp\/v2\/posts\/3548\/revisions\/3550"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/info.e-med.co.il\/remsima\/wp-json\/wp\/v2\/media\/3549"}],"wp:attachment":[{"href":"https:\/\/info.e-med.co.il\/remsima\/wp-json\/wp\/v2\/media?parent=3548"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/info.e-med.co.il\/remsima\/wp-json\/wp\/v2\/categories?post=3548"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/info.e-med.co.il\/remsima\/wp-json\/wp\/v2\/tags?post=3548"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}